Biologics IP - A Strategic Review (TechVision)

  • ID: 3849616
  • Report
  • Region: Global
  • 71 Pages
  • Frost & Sullivan
1 of 4
Profiling Patenting Activity of 13 Major Pharma-biotech Companies in the Area of Biologics

FEATURED COMPANIES

  • AbbVie
  • AstraZeneca
  • Bristol-Myers Squibb
  • GSK
  • Novartis
  • Pfizer
  • MORE
This study provides a strategic overview of the patent activity of the 13 major pharma-biotech companies in the area of biologics. The biologics patent portfolios of these companies were analyzed and segmented by biologics type (e.g., peptides, antibodies, vaccines etc.) and therapeutic area for competitive benchmarking.

This study will help pharma-biotech companies understand the competitive landscape and the available white space from patenting perspective.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie
  • AstraZeneca
  • Bristol-Myers Squibb
  • GSK
  • Novartis
  • Pfizer
  • MORE
1. Executive Summary

2. Research Objective and Background

3. Research Scope and Methodology

4. Biologics Patent Portfolios of the Top 13 Major Pharma Companies

5. Overview of Biologics Patent Portfolio
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
- AbbVie
- Amgen
- AstraZeneca
- Bayer HealthCare
- Bristol-Myers Squibb
- Eli Lilly
- GSK
- Merck
- Novartis
- Novo Nordisk
- Pfizer
- Roche
- Sanofi
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll